The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) filing for Sol-Gel’s Epsolay, a 5% microencapsulated benzoyl peroxide cream for the treatment of inflammatory lesions of rosacea or papulopustular rosacea.
Many patients with rosacea have features that overlap more than one subtype of the condition. A recent publication serves as a compliment to the classification guide with the intention of guiding treatment and management options based on individual patient features.
Effects of a specialized skincare regimen for sensitive and redness-prone skin were investigated in an eight-week, prospective, controlled clinical trial enrolling 60 patients with rosacea. The intervention was associated with improvements in objectively measured erythema, rosacea symptoms, and health-related quality of life.
Experts offer insights into the inflammatory pathways involved in rosacea pathogenesis, the putative anti-inflammatory mechanisms of action of treatments for rosacea, and future therapeutic needs.
A study in twins highlights exacerbating factors for patients with rosacea and the importance of the microbiome.
A topical minocycline foam application appears effective and was well-tolerated by patients with moderate-to-severe papulopustular rosacea.
Botulinum toxin may help address erythema and flushing in patients with refractory rosacea, according to data presented by Hema Sundaram, MA, MD, FAAD, at the AAD Virtual Meeting Experience (VMX) on June 12.
A recent study aimed to elucidate the association between variations in the skin’s microbiome and the development of rosacea symptoms.
A recent study examined the patient-reported side effects and tolerability concerns associated with azelaic acid foam and metronidazole cream and gel preparations.